Press releases

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the upcoming healthcare conference in Marach 2025.

"2024 was one of the best years in the history of Boston Scientific,” said Mike Mahoney, chairman and CEO.

Data sets for two clinical trials show positive results for both FARAPULSE pulsed field ablation and the WATCHMAN device for treating Afib.

“Miriam has a broad base of HR experience with a demonstrated ability to lead large-scale business transformations,” said Mike Mahoney, Boston Scientific CEO.

Bolt Medical acquisition to expand cardiovascular portfolio, furthering Boston Scientific strategy to address coronary and peripheral artery disease.

Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief...

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and...